The U.S. Food and Drug Administration is moving toward allowing compounding pharmacies to produce more than a dozen injectable peptides that were banned because of potentially significant safety risks, the New York BPC 157 for athletes and injury treatment: Science, safety, and legal concerns In a major policy shift, the U.S. Food and Drug Administration is reconsidering restrictions on several controversial peptides, including trending compounds like BPC 157 and Melanotan II. The move comes as demand for FDA Peptide Reclassification 2026: What It Means for Providers Research Peptides In Minnesota: Why Not For Human Consumption Doesn't Protect You Holt Law